
Alembic Pharma clears USFDA inspection at Vadodara bioequivalence facility
The story in brief
Alembic Pharma's Vadodara facility passed the USFDA inspection from August 31 to September 10, 2026, with no Form 483 observations. The FDA conducted the onsite bioequivalence check as part of routine oversight. A Form 483 is issued if conditions may violate regulations. No observations indicate compliance, reinforcing the facility's adherence to USFDA standards.